View Older Stories

Apr 22, 2026 07:59AM Zymeworks (ZYME) Reiterated at Buy by Stifel After AACR Presentation

Apr 10, 2026 06:45AM H.C. Wainwright Reiterates Buy Rating on Zymeworks (ZYME)

Apr 9, 2026 06:01AM Zymeworks names new R&D head and chief business officer

Mar 3, 2026 09:24AM Zymeworks (ZYME) PT Raised to $47 at Stifel

Mar 3, 2026 05:09AM Zymeworks (ZYME) Reiterated at Market Outperform by Citizens After Q4 Results

Mar 2, 2026 02:56PM Jefferies Reiterates Buy Rating on Zymeworks (ZYME) following Q4

Mar 2, 2026 06:30AM Zymeworks (ZYME) Misses Q4 EPS by 55c

Mar 2, 2026 06:01AM Zymeworks secures $250 million in royalty-backed financing from Royalty Pharma

Jan 12, 2026 06:00AM Zymeworks appoints Brian Cherry to board, promotes executives

Jan 12, 2026 04:06AM Zymeworks outlines 2026 strategy with potential $440M milestones

Jan 7, 2026 05:13AM Zymeworks (ZYME) Reiterated at Market Outperform by Citizens: Shares Attractive

Jan 7, 2026 05:07AM B.Riley Reiterates Buy Rating on Zymeworks (ZYME)

Dec 17, 2025 06:06AM Truist Securities Initiates Buy Rating on Zymeworks (ZYME)

Dec 12, 2025 05:08AM Wells Fargo Upgrades Zymeworks (ZYME) to Overweight

Dec 3, 2025 03:15AM Citizens Starts Zymeworks (ZYME) at Market Outperform

Nov 19, 2025 02:40PM Zymeworks (ZYME) PT Raised to $40 at Leerink Partners

Nov 19, 2025 05:31AM Zymeworks (ZYME) PT Raised to $25 at Wells Fargo

Nov 19, 2025 04:27AM Zymeworks (ZYME) PT Raised to $40 at Stifel

Nov 18, 2025 06:50AM Zymeworks (ZYME) PT Raised to $32 at H.C. Wainwright

Nov 18, 2025 05:12AM Zymeworks names Scott Platshon as acting chief investment officer

Nov 18, 2025 05:12AM Zymeworks shifts strategy to focus on royalty-driven growth model

Nov 17, 2025 02:07PM Zymeworks (ZYME) PT Raised to $37 at Leerink Partners

Nov 17, 2025 01:15PM Zymeworks (ZYME) PT Raised to $35 at Citi

Nov 6, 2025 05:02PM Zymeworks (ZYME) Misses Q3 EPS by 26c

Oct 27, 2025 06:51AM H.C. Wainwright Reiterates Buy Rating on Zymeworks (ZYME)

Oct 24, 2025 02:51AM Wells Fargo Assumes Zymeworks (ZYME) at Equal Weight

Oct 14, 2025 06:08AM H.C. Wainwright Upgrades Zymeworks (ZYME) to Buy

Oct 10, 2025 03:04AM B.Riley Starts Zymeworks (ZYME) at Buy

Oct 9, 2025 08:30AM InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

Aug 11, 2025 06:00AM Zymeworks adds two directors to board of directors

Aug 7, 2025 05:48PM Zymeworks (ZYME) Tops Q2 EPS by 3c

Jul 28, 2025 06:01AM Zymeworks gets FDA clearance for liver cancer drug trial

Jul 3, 2025 06:47AM H.C. Wainwright Reiterates Neutral Rating on Zymeworks (ZYME)

Jun 3, 2025 07:24AM Stifel Reiterates Buy Rating on Zymeworks (ZYME)

Jun 3, 2025 06:25AM Stifel Reiterates Buy Rating on Zymeworks (ZYME)

Jun 2, 2025 06:49AM H.C. Wainwright Reiterates Neutral Rating on Zymeworks (ZYME)

May 30, 2025 06:10AM Zymeworks (ZYME) Announces NMPA Approval of Zanidatamab in China

May 20, 2025 05:31AM TD Cowen Starts Zymeworks (ZYME) at Buy

May 8, 2025 06:24PM Zymeworks (ZYME) Misses Q1 EPS by 30c

Mar 11, 2025 06:42AM Zymeworks (ZYME) PT Raised to $13 at H.C. Wainwright

Mar 6, 2025 09:59AM Stifel Reiterates Buy Rating on Zymeworks (ZYME)

Mar 6, 2025 06:09AM Zymeworks (ZYME) PT Raised to $19 at Citi

Mar 5, 2025 04:30PM Zymeworks (ZYME) Misses Q4 EPS by 31c

Feb 26, 2025 06:07AM Zymeworks (ZYME) Achieves $14M Milestone from GSK Collaboration

Dec 16, 2024 06:16AM JPMorgan Upgrades Zymeworks (ZYME) to Overweight

Dec 12, 2024 08:33AM Zymeworks (ZYME) Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

Nov 21, 2024 09:22AM Zymeworks (ZYME) PT Raised to $26 at Leerink Partners

Nov 21, 2024 06:01AM Zymeworks (ZYME): FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated

Nov 7, 2024 06:19AM Leerink Partners Upgrades Zymeworks (ZYME) to Outperform, 'Time to Get Constructive on ZYME?'

Nov 1, 2024 07:25AM Wells Fargo Downgrades Zymeworks (ZYME) to Equal Weight

View Older Stories